Challenges of scale-up to dolutegravir-based regimens in sub-Saharan Africa-Reference-Cited by-同舟云学术

Challenges of scale-up to dolutegravir-based regimens in sub-Saharan Africa

Published:2020-04-01 Issue:5 Volume:34 Page:783-787
ISSN:0269-9370
Container-title:AIDS
language:en
Short-container-title:

Author:

Salou Mounerou,Butel Christelle,Comlan Adjo S.,Konou Abla A.,Tegueni Kokou,Ehlan Amivi,Lack Fiali,Dossim Sika,Ayouba Ahidjo,Delaporte Eric,Dagnra Anoumou Y.,Peeters Martine

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Infectious Diseases,Immunology,Immunology and Allergy

Reference16 articles.

1. HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis;Gupta;Lancet Infect Dis,2018

2. Key factors influencing the emergence of human immunodeficiency virus drug resistance in low- and middle-income countries;Wallis;J Infect Dis,2017

3. Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling study;Phillips;Lancet HIV,2018

4. Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, noninferiority, phase 3b trial;Aboud;Lancet Infect Dis,2019

5. Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: uncertainties and opportunities for implementation and research;Dorward;Lancet HIV,2018

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Virologic Failure and Drug Resistance After Programmatic Switching to Dolutegravir-based First-line Antiretroviral Therapy in Malawi and Zambia;Clinical Infectious Diseases;2024-06-07

2. Disparities in access to Dolutegravir in West African children, adolescents and young adults aged 0-24 years living with HIV. A IeDEA Pediatric West African cohort analysis;2024-05-25

3. Pharmaco-virological Outcomes and Genotypic Resistance Profiles Among Children and Adolescents Receiving a Dolutegravir (DTG)-Based Regimen in Togo;Clinical Infectious Diseases;2024-05-15

4. Early Effects of Scaling Up Dolutegravir-Based ARV Regimens Among Children Living with HIV in Malawi;AIDS and Behavior;2024-04-13

5. Detection of Arv-Resistant Mutants in HIV-1-Infected Individuals in a Context of Systematic Switching to an Association Based on Dolutegravir in Abidjan, Côte d’Ivoire;American Journal of Molecular Biology;2024